A Cross-sectional Investigation on the Prevalence of Functional Constipation and the Characteristics of Traditional Chinese Medicine Syndromes among the Elderly in Tianjin

开始日期2024-09-30

申办/合作机构

天津中医药大学

ITMCTR2024000204

/ SuspendedN/AIIT

Traditional Chinese medicine active healthy population cohort study

开始日期2024-08-16

申办/合作机构

天津中医药大学

100 项与天津中医药大学相关的临床结果

登录后查看更多信息

0 项与天津中医药大学相关的专利（医药）

登录后查看更多信息

8,194

项与天津中医药大学相关的文献（医药）

2025-12-01·INFLAMMATION RESEARCH

Mechanisms of mitochondrial damage-associated molecular patterns associated with inflammatory response in cardiovascular diseases

Review

作者: Guan, Xiuju ; Li, Haitao ; Zhang, Lijuan ; Zhi, Hongwei

Cardiovascular diseases (CVDs) continue to be a substantial global healthcare burden despite considerable progress in therapies. The inflammatory response during the progression of CVD has attracted considerable attention. Mitochondria serve as the principal energy source for the heart. In cardiovascular illnesses, mitochondrial homeostasis is disrupted, accompanied by structural and functional impairments. During mitochondrial stress or injury, mitochondrial damage-associated molecular patterns (mtDAMPs), such as mitochondrial DNA, cardiolipin, N-formyl peptide, and adenosine triphosphate, are released to activate pattern recognition receptors and trigger immunological responses. Inflammatory responses mediated by mtDAMPs substantially contribute to the pathophysiology of cardiovascular illnesses. In this review, we discuss the molecular mechanisms by which different mtDAMPs control the inflammatory response, address the pathological consequences of mtDAMPs in inducing or exacerbating the inflammatory response in CVDs, and summarize potential therapeutic targets in relevant experimental studies. Preventing or reducing mtDAMP release may play a role in CVD progression by alleviating the inflammatory response.

2025-12-01·Asia-Pacific Journal of Oncology Nursing

Evidence summary on management strategies for gastroesophageal reflux symptoms in patients following esophageal cancer surgery

Review

作者: Li, Huixia ; Fu, Yaxin ; Zhao, Shengjiang ; Zhang, Wei ; Zhao, Yuqing

Objective:

This study aimed to summarize evidence-based strategies for the self-management of gastroesophageal reflux symptoms (GERS) at home among patients who have undergone esophageal cancer surgery, providing practical references for clinical practice.

Methods:

A systematic evidence summary was conducted based on the reporting standards of the Fudan University Center for Evidence-based Nursing. Literature was retrieved from international and Chinese databases, including guidelines, expert consensus, systematic reviews, and original studies. The search covered the period from the inception of the databases to June 30, 2024. Two independent reviewers appraised the quality of evidence and synthesized recommendations across six domains: reflux symptoms, assessment, treatment, health education, follow-up, and outcome indicators.

Results:

A total of 25 high-quality studies were included, comprising 10 guidelines, 10 expert consensus documents, two systematic reviews, and three original studies. Thirty-four evidence items were synthesized, emphasizing a combination of pharmacological treatments, lifestyle modifications, and health education to improve self-management outcomes.

Conclusions:

This evidence synthesis highlights effective strategies for home-based self-management of GERS after esophageal cancer surgery. Future research should focus on culturally tailored interventions and large-scale studies to further enhance the applicability and reliability of these findings.

Trial registration:

This study was registered at the Fudan University Center for Evidence-Based Nursing (Registration No. ES202446701).

2025-11-01·CURRENT DRUG METABOLISM

Umbelliferone Enhances Immune Function in Cyclophosphamide-Induced Immunosuppressed Mice via Histidine and Purine Metabolism Regulation

Article

作者: Wang, Li ; Li, Mei ; Xing, Liwei ; Wan, Qianqian ; Xia, Yafei ; Huo, Bingjie ; Pei, Huan ; Cui, Huantian ; Wang, Yuming ; Wang, Jing

Background::

Chemotherapy-induced immunosuppression significantly impacts patient’s quality of life. Umbelliferone (UMB) is known for its anti-inflammatory, antioxidant, and anti-apoptotic properties, but its effects on cyclophosphamide (CTX)-induced immunosuppression need further study.

Methods::

We established a CTX-induced immunosuppressed mouse model and administered varying doses of UMB. Immune function was assessed by evaluating white blood cells, lymphocytes, thymus and spleen indices, and CD4+/CD8+ T cell ratios. Serum levels of IL-2, IFN-γ, IgA, IgM, and IgG, along with macrophage phagocytic activity, NK cytotoxicity, and lymphocyte proliferation, were measured. Untargeted metabolomics was used to identify key pathways regulated by UMB, and RT-qPCR and Western blotting were performed to analyze the expression of related enzymes and metabolites.

Results::

UMB intervention increased white blood cells, lymphocytes, thymus and spleen indices, and CD4+/CD8+ T cell ratios in CTX-immunosuppressed mice. It reversed reduced levels of serum IL-2, IFN-γ, IgA, IgM, and IgG and improved macrophage phagocytic activity, NK cytotoxicity, and lymphocyte proliferation. Key pathways identified by metabolomics included histidine and purine metabolism. UMB improved levels of histamine, L-glutamate, L-aspartate, xanthine, dAMP, deoxyinosine, xanthosine, and cGMP and upregulated HDC, ASPA, and PNP while downregulating XDH, PDE5, ROS, and MDA in spleen tissue. UMB enhanced SOD activity and GSH levels and reduced apoptosis, as indicated by lower TUNEL-positive expression.

Conclusion::

UMB enhanced immune function in CTX-immunosuppressed mice through the regulation of histidine and purine metabolism, exhibiting antioxidant and anti-apoptotic effects. These findings highlight the potential of UMB in mitigating immunosuppression.

项与天津中医药大学相关的新闻（医药）

2024-10-29

·PRNewswire

The 21st World Congress of Chinese Medicine - Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris

PAIRS, Oct. 28, 2024 /PRNewswire/ -- On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. Continue Reading (Group Photo at the Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases) A key highlight of the WCCM was the Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases on October 26. Hosted by the Industry-Education Integration Promotion Committee of the World Federation of Chinese Medicine Societies (WFCMS) and organized by Jimon Group, the seminar highlighted the latest research achievements and clinical applications of Chinese medicine in cardiovascular diseases. The event aimed to explore the significant value of Chinese medicine in the prevention and treatment of cardiovascular and cerebrovascular diseases, promote in-depth integration of traditional Chinese and modern medicine, and enhance benefits for patients worldwide. Ramon Maria Calduch, Chairman of the Supervisory Board of the WFCMS; Zhang Boli, Vice President of the WFCMS, Senior Researcher at the Chinese Academy of Engineering, and a leading practitioner in Chinese medicine; and Niu Liwei, Vice President of the WFCMS Industry-Education Integration Promotion Committee and Chairman of Jimon Group were among the eminent attendees. Other celebrated participants included Liu Xiaohan, Secretary of the Hebei Pharmaceutical Industry Association, and Wang Yi, Secretary of the Party Committee of the Institute of Chinese Medicine at Tianjin University of Traditional Chinese Medicine. During the launch of the Chinese Medicine for Global Health Industry Expansion Plan, the Jimon Group Chairman, Mr. Niu, elaborated on the landmark initiative. He explained that Jimon Group intends to further the international expansion of Chinese medicine, and establish a Chinese Medicine Industry-Education Integration Expansion Center in Paris, with the goal of contributing its expertise and resources to the creation of a global health community. The WCCM also featured a signing ceremony to formalize collaborations between Jimon Group and several entities, including the WFCMS Industry-Education Integration Promotion Committee, the Association des Ingénieurs Chinois en France, the International Chinese Medicine and Healthcare General Association of the U.S.A., and Canada-based United Wings Enterprise Inc. Through these partnerships, Jimon Group seeks to expand its market reach while enhancing the adaptability and competitiveness of its products by utilizing local resources. The ultimate goal is to broaden the reach and improve the recognition and implementation of Chinese medicine in global health practices. During the roundtable dialogue session, leading practitioners and researchers engaged in a lively discussion on the progress and future of Chinese medicine in treating cardiovascular and cerebrovascular diseases. Eminent leaders in the field from Germany, Australia, and Canada exchanged ideas on the global expansion of Chinese medicine, focusing on its cultural inheritance, innovations, and international collaboration. Jimon Group's involvement in the WCCM not only showcased its robust capabilities and remarkable achievements in the realm of Chinese medicine, but also highlighted its role in advancing the practice on a global scale. Looking forward, the company remains committed to its mission of "Inheriting the culture of Chinese medicine and leading the future of health," with plans to increase its investment in scientific research. In doing so, Jimon Group aims to champion both the cultural heritage and the latest innovations in Chinese medicine, striving to substantially impact the global prevention and treatment of cardiovascular and cerebrovascular diseases. SOURCE Jimon Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-04-02

·美通社

固生堂发布2023年度业绩公告：业绩持续增长，盈利稳健提升

广州 2024年4月2日 /美通社/ -- 3月27日，固生堂（2273.HK）发布2023年度业绩公告。期内，公司营收23.23亿元，同比增长43%；经调整净利润3.05亿元，同比增长53.6%。固生堂延续了上一年度的强劲增长势头，用亮眼的财报数据证实了自身良好的基本面和优异的成长性。固生堂2023年回购1.43亿港币，分红9800万港币，自费收入占比较高，现金流和现金储备充沛，管理层表示公司未来将保持业务高增速的同时，给予投资者不错的回报。门店拓展方面，公司自建和并购顺利推进，业务版图继续扩大。年内，固生堂如期推进佛山禅城、福州陆壹两家自建店，完成收购昆山铭泰、无锡李同丰、武汉颐德、宝中堂崂山、宝中堂峨山等5家分院，新拓展武汉、昆山2个城市，线下中医诊疗机构增至56家，覆盖全国16座城市。伴随业务版图的扩大，固生堂的医生队伍也在同步发展壮大。公司线上线下医生数量同比净增加7793人，达37,224名。其中，具有高级职称的医生人数净增加2613人至14437人，线下高级职称医生占比上升至49%，名医资源领跑民营中医医疗机构。此外，公司自有医生培养取得良好成效，自有医生业绩占比从2022年的25.8%上升至34.6%，有望为公司未来的业绩表现注入更多的增长动能。在公司精细化运营加持下，客户粘性持续提升。2023年固生堂门诊人次同比增长53%至430万，线下业绩同比增长49.2%，患者回头率由64%进一步增至65.2%。会员数量更是从2022年的164,942人跃升至318,383人，大幅增长93%，会员收入占线下收入比例提升至47%，公司品牌口碑向好，客户粘性提升，赢得了客户广泛的认可和信赖。同时，固生堂医联体合作稳步推进。2023年，固生堂与湖北中医药大学、天津中医药大学、湖南中医药大学、黑龙江中医药大学、湖北省中医院、湖南中医药大学第一附属医院等11家大学、中医院签署医联体合作，在人才培养、科学研究、医疗建设等多方面展开深入合作，固生堂的发展模式获得了公立体系的认可和支持。此外，固生堂亦加快推进院内制剂研发及科技创新，推动中医药传承精华、守正创新。院内制剂方面，公司的健脾化脂膏、松贞益发颗粒、养阳固精膏、益肾填精膏、河车固肾膏、孕保膏、岗桔清咽颗粒等7个院内制剂已成功获得药监局备案。科技创新方面，固生堂去年与百度、华西医院中国循证医学中心合作，共建中药大模型临床一体化平台，以中医AI技术赋能医生，提升诊疗效率，为公司后续发展提供长远助益。在企业社会责任方面，公司践行初心使命，诠释企业担当。2023年固生堂在各地开展中医义诊达 3181场次，服务民众超8.5万人。同时，公司通过互联网医院平台，帮助北京、上海、广州三大医疗中心的外地患者节省大量复诊开销和时间，帮助群众解决看病难、看病贵的问题。公司助力乡村振兴建设，通过采购中药材帮助种植农民增加收入。按照2022年全国12.3亿中医诊疗人次计算，固生堂目前在中医服务市场占有率约0.35%，公司已合作中医师占全国中医师数量4.9%，与市场占有率对比来看，未来有巨大的成长空间。【固生堂中医简介】：固生堂中医连锁管理集团（简称"固生堂"），成立于2010年，总部位于中国广州，是国内领先的集中医诊疗、药品研发、中医人才培养等于一体的中医连锁管理集团。2021年12月10日，固生堂在香港证券交易所挂牌上市（股票代码为02273.HK），成为"中医医疗连锁服务机构第一股"。自成立以来，固生堂以"医好、药好、服务好"为核心经营理念，为广大民众提供优质基层中医诊疗服务。同时，固生堂通过数字化和"互联网+"为医疗服务赋能，成功构建了"线上+线下"OMO服务模式，有效解决了区域间医师资源不平衡等痛点，满足患者多样化的医疗服务需求，践行初心使命，实现"让中医成为世界主流医学的一部分"的企业愿景。截至2023年12月31日，固生堂在全国16个城市开设56家线下中医诊疗机构，线上线下医疗平台服务网络覆盖北京、上海、广州、深圳、佛山、苏州等340余座城市。固生堂执业中医师超过3.7万名，其中，执业出诊的国医大师达到9位，名医数量领跑民营中医医疗机构，累计服务客户超过1500万人次。【公司官网网址】： https://www.gstzy.cn/

财报并购

2024-02-09

·今日头条

特别推荐 | 8分钟重温2023年《肠·道》演讲金句

14个学术主题，30位知名专家，547分钟时长，汇成了2023年《肠·道》演讲。作为“肠道专业人士的招牌演讲”，《肠·道》演讲已走过了6年。截至2023年12月31日，热心肠研究院累计邀请160位讲者，分享了他们对肠道产学研领域的真知灼见与实践感悟。如今，我们集锦2023年《肠·道》演讲的专家金句制成此视频，在新春来临之际，特别献给那些深耕肠道的业界同仁与关注肠道健康的朋友！我们关注微生态，也关注同一健康蓝灿辉热心肠智库专家热心肠生物技术研究院董事长兼院长我们大家都在关注微生态，尤其是肠道微生态。应该来说就是我们站在一个生态系统的这种角度，把中国传统的天人合一与西方现在用生态的理念去看人体、看自然环境，能够吻合和统一起来。吴崇明热心肠智库专家天津中医药大学研究员在每个人的肠道都定植一个由成百上千种肠道细菌构成的茂密森林，如何能够定向地将变异的菌群恢复到正常状态，使我们的健康得到改善，这是一个重要的问题。蒋超热心肠智库专家浙江大学生命科学研究院研究员暴露组作为一个相对来说比较新的领域，其实它是有非常重要的作用。“同一健康”的概念里面强调，我们必须得对人，还有环境以及动物的健康进行统一的研究。褚海燕热心肠智库专家中国科学院南京土壤研究所研究员过去我们把土壤当成惰性的化学介质，在土壤上修路、盖房子、种庄稼。实际上土壤是有生命的，土壤中的生物赋予了土壤的生命性。张志刚热心肠智库专家云南大学研究员我们就提出这样一个理念，关注全球的水资源的健康和水体的健康，也就是关注我们的肠道的健康，最终也就是关注我们自己的健康。王敬文热心肠智库专家复旦大学生命科学学院研究员思想家魏源曾经说过一句话：“师夷长技以制夷”。我们现在也就是正在从通过对虫媒肠道微生物的学习，最终研发出如何控制蜱虫传病的方法。我们关注人的肠道，也关注动物的肠道于政权热心肠智库专家中国农业大学生物学院教授肠道干细胞的两类调控因子，一类是肠道干细胞内源性的调控因子，一类是间充质微环境的调控因子，肠道干细胞的功能于肠道稳态至关重要。梁冠翔热心肠智库专家清华大学医学院助理教授到至今为止，其实我们一直没有证据能显示，妊娠期的子宫内有活性的微生物组，在不断地扩增、复制、释放活性的代谢产物。左涛热心肠智库专家中山大学附属第六医院研究员肠道病毒作为肠道细菌的伙伴，其在人体肠道中的存在数量是细菌总量的1~10倍，目前60%以上的人类的肠道病毒其实还从未被解析过。王修启热心肠智库专家华南农业大学动物科学学院研究员通过我们的研究发现，胞外谷氨酸与细胞膜上的G蛋白偶联受体FZD7、EGFR、IR结合，可以激活β-catenin和mTORC1信号，增加蛋白质的合成，促进猪肠道干细胞扩增，调控肠道健康。陶诗煜热心肠智库专家华中农业大学动物科技学院副研究员从健康仔猪分离的特定乳酸菌及其分泌的胞外囊泡，通过控制炎症反应减轻腹泻症状，其中巨噬细胞的表型转化是缓解腹泻的必要条件。孔祥峰热心肠智库专家中国科学院亚热带农业生态研究所研究员日粮添加胆汁酸可以保护断奶仔猪的肝脏，促进肠道潜在有益菌的繁殖，促进正常体重仔猪结肠发育，减轻IUGR仔猪结肠损伤，改善它的通透性并改善结肠微生物的平衡。武圣儒热心肠智库专家西北农林科技大学动物科技学院副教授我们的团队过去、现在和将来都将以瘤胃微生物代谢为核心，整合胰腺淀粉酶分泌、肠道微生物代谢以及乳腺和肝脏代谢的相关研究，为提高奶畜的饲料转化效率和泌乳效率持续开展攻关研究。我们关注疾病治疗，也关注健康管理卞兆祥热心肠智库专家香港浸会大学中医药学院讲座教授肠道菌群的失常，这里面可以表现出来的是肠道菌群引起的代谢物质失常，再影响到肠道局部跟肠道的周身体系的症状。我们说通过改善肠道菌，可以让肠道不要那么激动。陈宁热心肠智库专家北京大学人民医院主任医师环境究竟是如何导致了肠道菌群的失衡？这仍然是我们在研究IBD发病机制当中的一个未解之谜。我和我的团队进行IBD发病机制的研究当中，我们把目光锁定了口腔。何丛南昌大学第一附属医院副主任医师我们又在想，肠道菌群失衡是通过何种机制促进胰腺炎的重症化呢？我们将目标聚焦于NLRP3炎症小体。林国乐热心肠智库专家北京协和医院主任医师五步筑牢我们抗肠癌的一个防线——防、筛、诊、治、康：在防和筛方面，我们提出一个新的理念叫数字药丸；在康复方面，我提出一个新的理念就是肠癌术后五年大学计划。刘志刚热心肠智库专家西北农林科技大学食品科学与工程学院教授限制饮食是具有延缓衰老的潜力的，我们将继续致力于探索能够模拟卡路里限制益处的饮食干预方式，并且探索多种方案的组合。王宇浩热心肠智库专家浙江大学转化医学研究院研究员通过人为改变肠道菌群的组成，比如服用某些能够提高 Snhg9 表达的益生菌，来降低肠道的脂质吸收效率，从而达到减肥的目的。张家超热心肠智库专家海南大学食品科学与工程学院通过高膳食纤维饮食模式，选择性地来激发肠道本地菌群与益生菌展开一个竞争性的共进化，这种方式能够有效地提升双歧杆菌的肠道适应性，也证明了饮食干预策略来驯化益生菌的一个可行性。郑晓皎热心肠智库专家上海交通大学医学院附属第六人民医院研究员在最近几年，我们一直把目光聚焦在一类非12羟基胆汁酸，也就是猪胆酸上，发现猪胆酸可以通过多靶点来调控糖脂代谢和免疫。陈连民热心肠智库专家南京医科大学/江苏省人民医院教授要关注心血管代谢健康，可能要更多地关注饮食的健康以及肠道微生态的健康，而不用太去计较我们与生俱来的遗传的先天性决定因素。我们关注新理念新技术，也关注产业转化王琰热心肠智库专家中国医学学科学院药物研究所研究员当肠道菌群遇见药物的时候，实际上是开辟了药学研究的一个新领域，并助力我们认知药物在临床的个性化治疗。刘宏伟热心肠智库专家中国科学院微生物研究所研究员中药的现代化，必须要从肠道微生物的角度去认识和挖掘，阐明中药通过肠道微生物发挥重要作用的机制，必将为中药现代化做出重要的贡献。陈启仪热心肠智库专家上海市第十人民医院副主任医师在国际当中，复杂性、难治性、慢性、功能障碍性疾病，炎症性或者是肠道为主的肠道外疾病，肠菌移植都在临床逐渐的应用。作为长期有效的、能够走长远的一条路来讲，我们可能会将药品的研发作为一个新的选择。崔伯塔热心肠智库专家南京医科大学第二附属医院副教授让菌群移植像输血一样安全高效，从很粗的菌群的移植到洗涤菌群，到将来也可能精准化菌群移植的输注，这是未来的一个发展的趋势。郝梓凯热心肠智库专家北京理工大学生命学院副教授我们发现“月宫一号”可以最大限度地保持影响微生物-肠-脑轴的因素基本不变，并且最大限度地避免非精神因素对微生物-肠-脑轴的影响，是挖掘精神益生菌的理想实验平台。张佳中国科学院青岛生物能源与工程研究所副研究员目前益生菌的快检技术应用的范围会越来越广泛，包括食品、医药、农业等等。SCIVVS技术作为一项具有广泛应用前景的质检技术，必将为人类健康保驾护航。苏晓泉热心肠智库专家青岛大学计算机科学技术学院教授利用大数据和搜索引擎，我们提供了菌群检测中的一些问题的新的解决方案。所以大模型的发展有可能让我们重新认识菌群，获得一些不一样的理解。 Johanna Maukonen IFF Health全球临床研究与转化总监无论益生菌还是下一代益生菌，都需要更多的作用机制数据，来真正获得转化的潜力，还会有很多伟大的事情将要发生。未来会有什么机遇呢？请持续关注！

微生物疗法

100 项与天津中医药大学相关的药物交易

登录后查看更多信息

100 项与天津中医药大学相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年03月31日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

加参片	冠心病更多	临床2期
三叶片	2型糖尿病更多	临床2期
CN118236500 ( PD-1 )专利挖掘	肝病更多	药物发现
丹知青娥片	更年期综合症更多	终止
肝清颗粒	代谢功能障碍相关的脂肪肝病更多	无进展